{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:04:15Z","timestamp":1793880255010,"version":"4.7.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R15AI176177-01A1"],"award-info":[{"award-number":["1R15AI176177-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016747","name":"Mercer University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcyt.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:11:57Z","timestamp":1737400317000},"page":"597-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase"],"prefix":"10.1016","volume":"27","author":[{"given":"Tyler U.","family":"Faircloth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3648-3819","authenticated-orcid":false,"given":"Sara","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-8175","authenticated-orcid":false,"given":"Hamed","family":"Massoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-0517","authenticated-orcid":false,"given":"Elmira","family":"Jalilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Djalilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-4497","authenticated-orcid":false,"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1877-8975","authenticated-orcid":false,"given":"Raghavan","family":"Chinnadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2025.01.009_bib0001","first-page":"267","article-title":"Fibroblast precursors in normal and irradiated mouse hematopoietic organs","volume":"4","author":"Friedenstein","year":"1976","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/stcltm\/szab009","article-title":"Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review","volume":"11","author":"Renesme","year":"2022","journal-title":"Stem Cells Transl Med"},{"issue":"30","key":"10.1016\/j.jcyt.2025.01.009_bib0004","doi-asserted-by":"crossref","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies","volume":"6","author":"Levy","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1192636","article-title":"Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis","volume":"14","author":"Chinnadurai","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.01.009_bib0006","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.jcyt.2025.01.009_bib0007","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/sctm.19-0044","article-title":"Challenges in clinical development of mesenchymal stromal\/stem cells: concise review","volume":"8","author":"Mastrolia","year":"2019","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.009_bib0008","doi-asserted-by":"crossref","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.009_bib0009","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell Committee Position Statement on Nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of msc products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.009_bib0011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/sctm.19-0193","article-title":"Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia","volume":"9","author":"Augustine","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0012","doi-asserted-by":"crossref","first-page":"21507","DOI":"10.1038\/srep21507","article-title":"Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers","volume":"6","author":"Billing","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.009_bib0013","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcyt.2012.11.005","article-title":"Mesenchymal stromal cells: misconceptions and evolving concepts","volume":"15","author":"Phinney","year":"2013","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.009_bib0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni1328","article-title":"See no evil, hear no evil, do no evil: the lessons of immune privilege","volume":"7","author":"Niederkorn","year":"2006","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.01.009_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.009_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/imm.12716","article-title":"Mucosal immune tolerance at the ocular surface in health and disease","volume":"150","author":"Galletti","year":"2017","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0192623320978396","article-title":"Immunology and pathology in ocular drug development","volume":"49","author":"Ramos","year":"2021","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8620172","article-title":"The role of limbal epithelial stem cells in regulating corneal (lymph)angiogenic privilege and the micromilieu of the limbal niche following UV exposure","volume":"2018","author":"Notara","year":"2018","journal-title":"Stem Cells Int"},{"issue":"7114","key":"10.1016\/j.jcyt.2025.01.009_bib0019","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"issue":"30","key":"10.1016\/j.jcyt.2025.01.009_bib0020","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":"Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"266","key":"10.1016\/j.jcyt.2025.01.009_bib0021","doi-asserted-by":"crossref","first-page":"266ra172","DOI":"10.1126\/scitranslmed.3009644","article-title":"Human limbal biopsy-derived stromal stem cells prevent corneal scarring","volume":"6","author":"Basu","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.009_bib0022","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1167\/iovs.14-14999","article-title":"Human limbal mesenchymal cells support the growth of human corneal epithelial stem\/progenitor cells","volume":"55","author":"Nakatsu","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/sctm.20-0118","article-title":"Potential of mesenchymal stem cells as topical immunomodulatory cell therapies for ocular surface inflammatory disorders","volume":"10","author":"Beeken","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"10.1016\/j.jcyt.2025.01.009_bib0024","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1167\/iovs.17-22680","article-title":"Corneal mesenchymal stromal cells are directly antiangiogenic via PEDF and sFLT-1","volume":"58","author":"Eslani","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0025","first-page":"431","article-title":"Mesenchymal cells from limbal stroma of human eye","volume":"14","author":"Polisetty","year":"2008","journal-title":"Mol Vis"},{"issue":"12","key":"10.1016\/j.jcyt.2025.01.009_bib0026","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/02713683.2020.1762227","article-title":"Therapeutic effects of lyophilized conditioned-medium derived from corneal mesenchymal stromal cells on corneal epithelial wound healing","volume":"45","author":"Jabbehdari","year":"2020","journal-title":"Curr Eye Res"},{"issue":"11","key":"10.1016\/j.jcyt.2025.01.009_bib0027","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/ICO.0000000000002442","article-title":"The effect of mesenchymal stem cell secretome on corneal endothelial cell preservation in an oxidative injury model","volume":"39","author":"Rabiee","year":"2020","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.jcyt.2025.01.009_bib0028","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1167\/iovs.18-24803","article-title":"Effect of human corneal mesenchymal stromal cell-derived exosomes on corneal epithelial wound healing","volume":"59","author":"Samaeekia","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcrs.2018.09.030","article-title":"New ex vivo model of corneal endothelial phacoemulsification injury and rescue therapy with mesenchymal stromal cell secretome","volume":"45","author":"Rouhbakhshzaeri","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/tvst.9.3.26","article-title":"Reproducible derivation and expansion of corneal mesenchymal stromal cells for therapeutic applications","volume":"9","author":"Jabbehdari","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"10.1016\/j.jcyt.2025.01.009_bib0031","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcyt.2015.08.003","article-title":"Effect of culture medium on propagation and phenotype of corneal stroma-derived stem cells","volume":"17","author":"Sidney","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241241992","article-title":"Increased anti-inflammatory therapeutic potential and progenitor marker expression of corneal mesenchymal stem cells cultured in an optimized propagation medium","volume":"33","author":"Hopkinson","year":"2024","journal-title":"Cell Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.009_bib0033","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/stem.2781","article-title":"Cornea-derived mesenchymal stromal cells therapeutically modulate macrophage immunophenotype and angiogenic function","volume":"36","author":"Eslani","year":"2018","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcyt.2013.07.006","article-title":"Immunosuppressive properties of mesenchymal stromal cell cultures derived from the limbus of human and rabbit corneas","volume":"16","author":"Bray","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0035","first-page":"2087","article-title":"Stem cells isolated from the human stromal limbus possess immunosuppressant properties","volume":"18","author":"Garfias","year":"2012","journal-title":"Mol Vis"},{"issue":"8","key":"10.1016\/j.jcyt.2025.01.009_bib0036","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/stmcls\/sxae040","article-title":"Vascular endothelial growth factor secretion and immunosuppression are distinct potency mechanisms of human bone marrow mesenchymal stromal cells","volume":"42","author":"Faircloth","year":"2024","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.009_bib0037","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.009_bib0038","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.celrep.2018.02.013","article-title":"Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach","volume":"22","author":"Chinnadurai","year":"2018","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.009_bib0039","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","article-title":"Immunological characterization of multipotent mesenchymal stromal cells\u2013The International Society for Cellular Therapy (ISCT) working proposal","volume":"15","author":"Krampera","year":"2013","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.009_bib0040","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/stcltm\/szac050","article-title":"Chemokine assay matrix defines the potency of human bone marrow mesenchymal stromal cells","volume":"11","author":"Lipat","year":"2022","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.009_bib0041","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0042","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcyt.2018.10.014","article-title":"Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency","volume":"21","author":"Robb","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0043","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pathol-011110-130230","article-title":"Mesenchymal stem cells: mechanisms of inflammation","volume":"6","author":"Singer","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.009_bib0044","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.stem.2021.09.006","article-title":"Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy","volume":"28","author":"Krampera","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-9255-8-25","article-title":"Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts","volume":"8","author":"Asp","year":"2011","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-031-30040-0_6","article-title":"Advanced technologies for potency assay measurement","volume":"1420","author":"Chinnadurai","year":"2023","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0047","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00003226-199905000-00013","article-title":"Protection of corneal allografts by CTLA4-Ig","volume":"18","author":"Gebhardt","year":"1999","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.009_bib0048","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1167\/iovs.03-0084","article-title":"Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection","volume":"44","author":"Ardjomand","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.jcyt.2025.01.009_bib0049","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.4049\/jimmunol.179.6.3672","article-title":"The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival","volume":"179","author":"Shen","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.009_bib0050","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.1301828","article-title":"IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells","volume":"192","author":"Chinnadurai","year":"2014","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.01.009_bib0051","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41409-024-02321-3","article-title":"Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation","volume":"59","author":"Singh","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.01.009_bib0052","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtos.2022.06.004","article-title":"Impact of aging on the pathophysiology of dry eye disease: A systematic review and meta-analysis","volume":"25","author":"Kitazawa","year":"2022","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.jcyt.2025.01.009_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102933","article-title":"Autoimmunity in dry eye disease\u2014An updated review of evidence on effector and memory Th17 cells in disease pathogenicity","volume":"20","author":"Chen","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jcyt.2025.01.009_bib0054","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/09273948.2021.1939390","article-title":"A review of ocular graft-versus-host disease: pathophysiology, clinical presentation and management","volume":"29","author":"Carreno-Galeano","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"416","key":"10.1016\/j.jcyt.2025.01.009_bib0055","doi-asserted-by":"crossref","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0056","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41536-024-00347-1","article-title":"MSCs mediate long-term efficacy in a Crohn's disease model by sustained anti-inflammatory macrophage programming via efferocytosis","volume":"9","author":"Dave","year":"2024","journal-title":"NPJ Regen Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.009_bib0057","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1038\/s41467-021-26834-3","article-title":"Mesenchymal stromal cell apoptosis is required for their therapeutic function","volume":"12","author":"Pang","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.009_bib0058","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcyt.2020.04.102","article-title":"Splenic macrophage phagocytosis of intravenously infused mesenchymal stromal cells attenuates tumor localization","volume":"23","author":"Hasgur","year":"2021","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.009_bib0059","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/ATVBAHA.122.318079","article-title":"CD8(+) T cells promote pathological angiogenesis in ocular neovascular disease","volume":"43","author":"Deliyanti","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.009_bib0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/02713683.2014.968934","article-title":"Critical role of IP-10 on reducing experimental corneal neovascularization","volume":"40","author":"Liu","year":"2015","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.009_bib0061","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jcyt.2018.02.003","article-title":"Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells","volume":"20","author":"Guan","year":"2018","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.009_bib0062","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/stem.2509","article-title":"Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression","volume":"35","author":"Davies","year":"2017","journal-title":"Stem Cells"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:34:20Z","timestamp":1777332860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1465324925000325"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}